Association of Transanal Total Mesorectal Excision With Local Recurrence of Rectal Cancer
- PMID: 33533932
- PMCID: PMC7859847
- DOI: 10.1001/jamanetworkopen.2020.36330
Association of Transanal Total Mesorectal Excision With Local Recurrence of Rectal Cancer
Erratum in
-
Errors in the Results Section of the Abstract.JAMA Netw Open. 2021 Mar 1;4(3):e213659. doi: 10.1001/jamanetworkopen.2021.3659. JAMA Netw Open. 2021. PMID: 33662128 Free PMC article. No abstract available.
Abstract
Importance: Proponents of novel transanal total mesorectal excision (TME) suggest the procedure overcomes the technical and oncologic challenges of conventional approaches for treating rectal cancer. Recently, however, there has been controversy regarding the oncologic safety of the procedure.
Objective: To assess the association of transanal TME with the incidence of local recurrence (LR) of cancer and the probability of remaining free of LR during follow-up.
Design, setting, and participants: This multicenter cohort study used data from 8 high-volume rectal cancer academic institutions from across Canada on all consecutive patients with primary rectal cancer treated by transanal TME at the participating centers. The study was conducted between January 2014 and December 2018, and data were analyzed from April 1, 2020, to September 15, 2020.
Exposure: Transanal TME.
Main outcomes and measures: The incidence of LR was reported as a direct measure of quality of resection. The cumulative probability of LR- and systemic recurrence (SR)-free survival at 36 months was estimated. Local recurrence and SR were defined as radiologic or endoscopic evidence of 1 or more new lesions in or outside the pelvis, respectively, documented during surveillance after the removal of the primary tumor.
Results: Of 608 total patients included in the analysis, 423 (69.6%) were male; the median age was 63 years (interquartile range [IQR], 54-70 years). Local recurrence was identified in 22 patients (3.6%) after a median follow-up of 27 months (IQR, 18-38 months). The median time to LR was 13 months (IQR, 9-19 months). Sixteen of the 22 patients with LR (72.7%) were male, 14 (63.6%) received neoadjuvant chemoradiation, and 12 (54.5%) had American Joint Committee on Cancer stage III disease. Of those with LR, 16 (72.7%) had a negative circumferential radial margin and 20 (90.9%) had a negative distal resection margin, 2 (9.1%) experienced conversion to open surgery, and 15 (68.2%) also developed SR. The probability of LR-free survival at 36 months was 96% (95% CI, 94%-98%). According to the Cox proportional hazards regression model, the hazard ratio of LR was estimated to be 4.2 (95% CI, 2.9-6.2) times higher among patients with a positive circumferential radial margin than among those with a negative circumferential radial margin.
Conclusions and relevance: In this cohort study, transanal TME performed by experienced surgeons was associated with an incidence of LR and SR that is in line with the published literature on open and laparoscopic TME, suggesting that transanal TME may be an acceptable approach for management of rectal cancer.
Conflict of interest statement
Figures
Similar articles
-
Oncologic outcomes following transanal total mesorectal excision: the United States experience.Surg Endosc. 2024 Jul;38(7):3703-3715. doi: 10.1007/s00464-024-10896-7. Epub 2024 May 23. Surg Endosc. 2024. PMID: 38782828
-
Long-term outcomes by a transanal approach to total mesorectal excision for rectal cancer.Surg Endosc. 2017 Dec;31(12):5248-5257. doi: 10.1007/s00464-017-5597-7. Epub 2017 Jun 22. Surg Endosc. 2017. PMID: 28643051
-
Statistical, Clinical, Methodological Evaluation of Local Recurrence Following Transanal Total Mesorectal Excision for Rectal Cancer: A Systematic Review.Dis Colon Rectum. 2021 Jul 1;64(7):899-914. doi: 10.1097/DCR.0000000000002110. Dis Colon Rectum. 2021. PMID: 33938532
-
Outcomes of open vs laparoscopic vs robotic vs transanal total mesorectal excision (TME) for rectal cancer: a network meta-analysis.Tech Coloproctol. 2023 May;27(5):345-360. doi: 10.1007/s10151-022-02739-1. Epub 2022 Dec 12. Tech Coloproctol. 2023. PMID: 36508067 Review.
-
A systematic review and meta-analysis of oncological outcomes with transanal total mesorectal excision for rectal cancer.Colorectal Dis. 2024 May;26(5):837-850. doi: 10.1111/codi.16982. Epub 2024 Apr 8. Colorectal Dis. 2024. PMID: 38590019 Review.
Cited by
-
Efficacy and long-term outcomes of abdominoperineal resection using transperineal total mesorectal excision approach for rectal cancer.Surg Today. 2024 Sep 17. doi: 10.1007/s00595-024-02937-4. Online ahead of print. Surg Today. 2024. PMID: 39287627
-
Transanal total mesorectal excision: short- and long-term results of four certified colorectal cancer centers in Germany.Int J Colorectal Dis. 2024 Aug 15;39(1):132. doi: 10.1007/s00384-024-04704-w. Int J Colorectal Dis. 2024. PMID: 39145821 Free PMC article.
-
Local Recurrence of Rectal Cancer After Transanal Total Mesorectal Excision and Risk Factors: A Nationwide Multicenter Cohort Study in Japan.Ann Surg Open. 2024 Jan 8;5(1):e369. doi: 10.1097/AS9.0000000000000369. eCollection 2024 Mar. Ann Surg Open. 2024. PMID: 38883940 Free PMC article.
-
Total mesorectal excision in MRI-defined low rectal cancer: multicentre study comparing oncological outcomes of robotic, laparoscopic and transanal total mesorectal excision in high-volume centres.BJS Open. 2024 May 8;8(3):zrae029. doi: 10.1093/bjsopen/zrae029. BJS Open. 2024. PMID: 38788679 Free PMC article.
-
Oncologic outcomes following transanal total mesorectal excision: the United States experience.Surg Endosc. 2024 Jul;38(7):3703-3715. doi: 10.1007/s00464-024-10896-7. Epub 2024 May 23. Surg Endosc. 2024. PMID: 38782828
References
-
- van der Pas MH, Haglind E, Cuesta MA, et al. ; COlorectal cancer Laparoscopic or Open Resection II (COLOR II) Study Group . Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. 2013;14(3):210-218. doi:10.1016/S1470-2045(13)70016-0 - DOI - PubMed
-
- Jeong SY, Park JW, Nam BH, et al. . Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(7):767-774. doi:10.1016/S1470-2045(14)70205-0 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
